News

Archus Orthopedics will use the venture loan to accelerate its growth and clinical development process. Jim Fitzsimmons, CEO at Archus, said: “GE Healthcare Financial Services’ in-depth knowledge of

Existing investors Lehman Brothers and Venrock Associates also participated in this financing round. John Tighe, president and CEO of Peak Surgical, said: “The size, valuation and timing of

Centocor has submitted the BLA for ustekinumab (CNTO 1275) in December 2007 based on its development program including data from two large phase III multicenter, randomized, double-blind, placebo-controlled

Acorda also acquired Neurorecovery’s preclinical and clinical data, regulatory filings, copyrights, trademarks and domain names relating to the three products. Two Phase II studies of the aminopyridine compound

The company said that the first patient enrolled in this study responded very favorably to veltuzumab. Prior to receiving a single dose of 80mg of veltuzumab, the patient

The agreement provides Aesculap with the right to sell in the US and includes minimum purchase requirements and the payment of a royalty on sales of disposables. Michael

The company said that the motavizumab biologics license application (BLA) is supported by clinical trial data from more than 6,000 patients in which safety and efficacy in prevention

CV Therapeutics has received Medlogics stock and is entitled to development milestone payments, royalties and other potential payments on future sales of any products incorporating the technology. Louis

Eyeonics now operates as a wholly-owned subsidiary of Bausch & Lomb. Its crystalens intraocular lens (IOL), the first and only FDA-approved accommodating IOL for the treatment of cataracts,